cagrilintide semaglutide cagrisema phase 3 results 2024 2025 Novo Nosedives on Underwhelming III Weight-Loss Data Novo Nordisk's CagriSema 2.4 mg

Weight regain was 13.9 lbs in those with no history of T2DM vs 11.5 lbs in those with a history of T2DM

Performance and analytics orientation: Experience defining and tracking program metrics, using data to identify issues and opportunities, and communicating insights to senior stakeholders

Population: What We Eat in America, NHANES 2009-2010. Dietary Data Brief , no

Treatment is not usually necessary unless the individual seeks cosmetic improvement

[1] [2] The Medicines and Healthcare products Regulatory Agency (MHRA) has approved this medication primarily for glycaemic control, while a higher dose formulation (Wegovy) is specifically licensed for weight management